Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review.
AmpC
Antibiotic therapy
Cephalosporinase
Enterobacteriaceae
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
17
03
2019
revised:
07
10
2019
accepted:
20
10
2019
pubmed:
5
11
2019
medline:
24
11
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
The burden of antibiotic-resistant infections among Gram-negative bacteria is increasing. Resistance to third-generation cephalosporins (3GCs) in Enterobacteriaceae is mainly conferred by the acquisition of β-lactamases or by deregulation of natural genetically-encoded β-lactamase enzymes. Enterobacteriaceae such as Enterobacter spp., Serratia marcescens, Citrobacter freundii, Providencia spp. and Morganella morganii (ESCPM group) possess chromosomally-encoded inducible AmpC β-lactamases. AmpC can be overproduced as a response to β-lactam antibiotic exposure or by constitutive dysfunction of the AmpC regulation system. This overproduction can lead to the inactivation of 3GCs. Based on small clinical studies, international guidelines and expert recommendations suggest that 3GCs should be avoided as definitive therapy for infections caused by ESCPM group organisms. In this narrative review, we discuss the published literature and evaluate the risk related to 3GC use in the case of documented ESCPM infection.
Identifiants
pubmed: 31682902
pii: S0924-8579(19)30295-X
doi: 10.1016/j.ijantimicag.2019.10.015
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Cephalosporins
0
AmpC beta-lactamases
EC 3.5.2.6
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105834Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.